Only a slightly decreased risk of asthenia (RR, 0.34; 95% CI, 0.14–0.82) and increased risk of neutropenia (RR, 1.14; 95% CI, 1.01–1.29) were seen in the overall population, suggesting that the PARP inhibitors are well-tolerated. Here, PARP1 is linked to neutropenia.